Humana (NYSE:HUM) Stock Rating Lowered by Leerink Partners

Humana (NYSE:HUM) was downgraded by Leerink Partners from an “outperform” rating to a “market perform” rating in a report issued on Wednesday, Marketbeat Ratings reports. They presently have a $250.00 price target on the insurance provider’s stock, down from their previous price target of $400.00. Leerink Partners’ target price points to a potential upside of 3.43% from the stock’s current price.

Other equities analysts also recently issued research reports about the company. Truist Financial raised their target price on Humana from $355.00 to $400.00 and gave the stock a “hold” rating in a research report on Monday, July 15th. Deutsche Bank Aktiengesellschaft upped their target price on shares of Humana from $341.00 to $349.00 and gave the stock a “hold” rating in a report on Friday, August 2nd. Royal Bank of Canada lifted their price target on shares of Humana from $385.00 to $400.00 and gave the company an “outperform” rating in a report on Thursday, September 5th. Stephens cut shares of Humana from an “overweight” rating to an “equal weight” rating and cut their target price for the company from $400.00 to $250.00 in a research note on Wednesday. Finally, Piper Sandler began coverage on Humana in a research report on Wednesday, June 26th. They set an “overweight” rating and a $392.00 price target on the stock. One equities research analyst has rated the stock with a sell rating, sixteen have assigned a hold rating and seven have issued a buy rating to the company’s stock. According to data from MarketBeat.com, the stock currently has an average rating of “Hold” and a consensus price target of $360.86.

Humana Stock Performance

HUM opened at $241.72 on Wednesday. The stock’s 50 day simple moving average is $340.75 and its 200-day simple moving average is $342.90. The company has a current ratio of 1.66, a quick ratio of 1.66 and a debt-to-equity ratio of 0.70. The stock has a market cap of $29.13 billion, a PE ratio of 15.05, a P/E/G ratio of 2.44 and a beta of 0.50. Humana has a 1 year low of $213.31 and a 1 year high of $530.54.

Humana (NYSE:HUM) last announced its quarterly earnings data on Wednesday, July 31st. The insurance provider reported $6.96 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $5.89 by $1.07. The company had revenue of $29.54 billion during the quarter, compared to analysts’ expectations of $28.52 billion. Humana had a net margin of 1.53% and a return on equity of 16.12%. The business’s revenue was up 10.4% on a year-over-year basis. During the same quarter in the prior year, the company posted $8.94 EPS. Sell-side analysts forecast that Humana will post 16.01 EPS for the current year.

Institutional Investors Weigh In On Humana

A number of institutional investors and hedge funds have recently added to or reduced their stakes in HUM. Pzena Investment Management LLC grew its position in shares of Humana by 538.7% during the 2nd quarter. Pzena Investment Management LLC now owns 2,318,347 shares of the insurance provider’s stock worth $866,250,000 after buying an additional 1,955,375 shares during the period. Ontario Teachers Pension Plan Board grew its holdings in Humana by 11,647.2% during the first quarter. Ontario Teachers Pension Plan Board now owns 1,059,478 shares of the insurance provider’s stock valued at $367,342,000 after purchasing an additional 1,050,459 shares during the period. Marshall Wace LLP increased its stake in Humana by 118.9% in the second quarter. Marshall Wace LLP now owns 1,425,302 shares of the insurance provider’s stock valued at $532,564,000 after purchasing an additional 774,085 shares in the last quarter. Putnam Investments LLC raised its holdings in Humana by 550.3% in the fourth quarter. Putnam Investments LLC now owns 875,489 shares of the insurance provider’s stock worth $400,808,000 after purchasing an additional 740,858 shares during the period. Finally, Steadfast Capital Management LP bought a new position in shares of Humana during the first quarter worth $158,813,000. Institutional investors own 92.38% of the company’s stock.

About Humana

Humana Inc, together with its subsidiaries, provides medical and specialty insurance products in the United States. It operates through two segments, Insurance and CenterWell. The company offers medical and supplemental benefit plans to individuals. It has a contract with Centers for Medicare and Medicaid Services to administer the Limited Income Newly Eligible Transition prescription drug plan program; and contracts with various states to provide Medicaid, dual eligible, and long-term support services benefits.